Long-acting injectable PrEP: An exciting alternative

519411

February 23, 2021

5 min read

Source/Disclosures

Published by:

Disclosures: Ross reports no relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The target to end the 40-year HIV/AIDS epidemic in the United States is 2030. However, the persistent threat of HIV/AIDS amid ongoing stigma has cast doubt that 2030 is a realistic goal.

As of the end of 2019, 32.7 million people had died from AIDS-related illnesses globally, with around 700,000 deaths occurring annually. In the U.S., an estimated 1.2 million Americans have HIV, including 37,968 new diagnoses in 2018. Reduced spread among individuals and across communities is attributable to advancements in pharmacological therapies when integrated with nonpharmacological prevention practices. PrEP and postexposure prophylaxis have proven to be effective strategies, but gaps in prevention still exist…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close